1.
Seaby EG, Leggatt G, Cheng G, et al. A gene pathogenicity tool "GenePy" identifies missed biallelic diagnoses in the 100,000 Genomes Project. Genetics in medicine : official journal of the American College of Medical Genetics. 2024;26(4):101073. doi:10.1016/j.gim.2024.101073.
1.
Pignolo RJ, Mukaddam MA, Baujat G, et al. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva. BMC medical research methodology. 2023;23(1):269. doi:10.1186/s12874-023-02080-7.
1.
Hills S, Li Q, Madden JA, et al. High number of candidate gene variants are identified as disease-causing in a period of 4 years. American journal of medical genetics. Part A. 2023. doi:10.1002/ajmg.a.63509.
1.
Seaby EG, Thomas S, Hunt D, et al. A Panel-Agnostic Strategy ’HiPPo’ Improves Diagnostic Efficiency in the UK Genomic Medicine Service. Healthcare (Basel, Switzerland). 2023;11(24). doi:10.3390/healthcare11243179.
1.
Stenton SL, O’Leary M, Lemire G, et al. Critical assessment of variant prioritization methods for rare disease diagnosis within the Rare Genomes Project. medRxiv : the preprint server for health sciences. 2023. doi:10.1101/2023.08.02.23293212.
1.
Martin-Geary AC, Blakes AJM, Dawes R, et al. Systematic identification of disease-causing promoter and untranslated region variants in 8,040 undiagnosed individuals with rare disease. medRxiv : the preprint server for health sciences. 2023. doi:10.1101/2023.09.12.23295416.
1.
Serrano JG, O’Leary M, VanNoy GE, et al. Advancing Understanding of Inequities in Rare Disease Genomics. Clinical therapeutics. 2023. doi:10.1016/j.clinthera.2023.06.010.